GREENWICH LIFESCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
GREENWICH LIFESCIENCES, INC. (GLSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.01 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2024-11-14
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-09-30 was -$2.69M, a 160.10% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-06-30 was -$594.52K.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-03-31 was $5.29M, a 163.29% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-12-31 was -$594.52K.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $5.89M, a 28.78% decline from fiscal 2022.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $8.26M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$3.28M derived: sum of 2 quarters · filed 2024-11-14 | $2.01M 10-Q · filed 2024-11-14 | $1.42M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | -$594.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $4.70M 10-Q · filed 2024-08-14 | $4.10M derived: sum of 3 quarters · filed 2024-08-14 | $8.57M derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $5.29M 10-Q · filed 2024-05-20 | $4.70M derived: sum of 2 quarters · filed 2024-05-20 | $9.17M derived: sum of 3 quarters · filed 2024-05-20 | $9.17M derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-12-31 | -$594.52K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $3.88M derived: sum of 2 quarters · filed 2024-04-15 | $3.88M derived: sum of 3 quarters · filed 2024-04-15 | $5.89M 10-K · filed 2024-04-15 |
| 2023-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | $4.47M derived: sum of 2 quarters · filed 2023-10-19 | $6.48M 10-Q · filed 2023-10-19 | $5.89M derived: sum of 4 quarters · filed 2023-10-19 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $2.01M 10-Q · filed 2023-08-21 | $1.42M derived: sum of 3 quarters · filed 2023-08-21 | $820.61K derived: sum of 4 quarters · filed 2023-08-21 |
| 2023-03-31 | $2.01M 10-Q · filed 2023-05-22 | $1.42M derived: sum of 2 quarters · filed 2023-05-22 | $820.61K derived: sum of 3 quarters · filed 2023-05-22 | |
| 2022-12-31 | -$594.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$1.19M derived: sum of 2 quarters · filed 2023-03-31 | $8.26M 10-K · filed 2023-03-31 | |
| 2022-09-30 | -$594.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $8.86M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $9.45M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |